Victor Abler

741 total citations
47 papers, 454 citations indexed

About

Victor Abler is a scholar working on Neurology, Psychiatry and Mental health and Cellular and Molecular Neuroscience. According to data from OpenAlex, Victor Abler has authored 47 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Neurology, 24 papers in Psychiatry and Mental health and 9 papers in Cellular and Molecular Neuroscience. Recurrent topics in Victor Abler's work include Parkinson's Disease Mechanisms and Treatments (24 papers), Neurological disorders and treatments (15 papers) and Schizophrenia research and treatment (15 papers). Victor Abler is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (24 papers), Neurological disorders and treatments (15 papers) and Schizophrenia research and treatment (15 papers). Victor Abler collaborates with scholars based in United States, United Kingdom and Canada. Victor Abler's co-authors include Benjamin Carroll, Nazia Rashid, Bruce Coate, Clive Ballard, Robert A. Hauser, Cheryl Fitzer‐Attas, Sanjay Gandhi, Ismaeel Yunusa, Krithika Rajagopalan and Rom E. Eliaz and has published in prestigious journals such as PLoS ONE, Brain and Neurology.

In The Last Decade

Victor Abler

43 papers receiving 433 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Victor Abler United States 14 252 158 131 61 51 47 454
P. De Domenico Italy 6 188 0.7× 121 0.8× 106 0.8× 42 0.7× 57 1.1× 15 367
Martha E. Trieschmann United States 7 340 1.3× 166 1.1× 100 0.8× 21 0.3× 39 0.8× 10 438
Sanjeet Pakrasi United Kingdom 12 157 0.6× 179 1.1× 107 0.8× 100 1.6× 90 1.8× 18 507
Tilak Mendis Canada 11 247 1.0× 90 0.6× 98 0.7× 47 0.8× 66 1.3× 15 414
Nataša Klepac Croatia 13 211 0.8× 129 0.8× 33 0.3× 63 1.0× 82 1.6× 28 487
Ariane Park United States 7 252 1.0× 82 0.5× 71 0.5× 44 0.7× 62 1.2× 8 379
C. Debieuvre United States 6 445 1.8× 74 0.5× 110 0.8× 13 0.2× 98 1.9× 9 519
Kathrin Marini Austria 10 196 0.8× 49 0.3× 58 0.4× 27 0.4× 53 1.0× 13 326
Margherita Torti Italy 14 318 1.3× 46 0.3× 91 0.7× 66 1.1× 27 0.5× 21 474
Daun Bahr United Kingdom 4 199 0.8× 78 0.5× 107 0.8× 27 0.4× 42 0.8× 7 321

Countries citing papers authored by Victor Abler

Since Specialization
Citations

This map shows the geographic impact of Victor Abler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victor Abler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victor Abler more than expected).

Fields of papers citing papers by Victor Abler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victor Abler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victor Abler. The network helps show where Victor Abler may publish in the future.

Co-authorship network of co-authors of Victor Abler

This figure shows the co-authorship network connecting the top 25 collaborators of Victor Abler. A scholar is included among the top collaborators of Victor Abler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victor Abler. Victor Abler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Downs, Jenny, et al.. (2025). Real‐world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study. Developmental Medicine & Child Neurology. 68(3). 407–417.
4.
Alva, Gus, et al.. (2024). Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study. Journal of Alzheimer s Disease. 98(1). 265–274. 5 indexed citations
5.
Isaacson, Stuart, Rajesh Pahwa, Fernando Pagán, Victor Abler, & Daniel Truong. (2024). Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis. Clinical Parkinsonism & Related Disorders. 10. 100256–100256. 1 indexed citations
6.
Weintraub, Daniel, Alberto J. Espay, Vibhash D. Sharma, et al.. (2023). Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial. Parkinsonism & Related Disorders. 119. 105951–105951. 4 indexed citations
7.
McGraw, Sarah, et al.. (2023). Meaningful Improvements in Rett Syndrome: A Qualitative Study of Caregivers. Journal of Child Neurology. 38(5). 270–282. 6 indexed citations
8.
Abler, Victor, et al.. (2022). Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis. Frontiers in Neurology. 13. 919778–919778. 5 indexed citations
9.
Yunusa, Ismaeel, et al.. (2022). Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis. Advances in Therapy. 39(5). 1993–2008. 23 indexed citations
10.
Isaacson, Stuart, Clive Ballard, Bruce Coate, et al.. (2021). Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients. Parkinsonism & Related Disorders. 87. 25–31. 14 indexed citations
11.
Yunusa, Ismaeel, Nazia Rashid, Victor Abler, & Krithika Rajagopalan. (2021). Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review. The Journal of Prevention of Alzheimer s Disease. 8(4). 520–533. 9 indexed citations
12.
Caroff, Stanley N., et al.. (2020). Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia. BMC Psychiatry. 20(1). 365–365. 7 indexed citations
13.
Alva, Gustavo, Jason Aldred, Bruce Coate, et al.. (2020). An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression. Journal of Parkinson s Disease. 10(4). 1751–1761. 13 indexed citations
14.
Ballard, Clive, Stuart Isaacson, James C. Norton, et al.. (2020). Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. Parkinsonism & Related Disorders. 77. 100–106. 30 indexed citations
15.
Loughlin, Anita M., Nancy D. Lin, Victor Abler, & Benjamin Carroll. (2019). Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States. PLoS ONE. 14(6). e0216044–e0216044. 21 indexed citations
16.
Caroff, Stanley N., et al.. (2018). Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. BMC Psychiatry. 18(1). 306–306. 20 indexed citations
17.
Krismer, Florian, Klaus Seppi, Gregor K. Wenning, et al.. (2018). Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. Parkinsonism & Related Disorders. 58. 23–27. 15 indexed citations
18.
Iyer, Ravi, Paul Wicks, Sanjay Gandhi, et al.. (2018). Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States. Patient. 11(5). 547–559. 20 indexed citations
19.
Abler, Victor, et al.. (2017). ESTIMATION OF EPIDEMIOLOGY OF TARDIVE DYSKINESIA IN THE UNITED STATES (P2.018). Neurology. 88(16_supplement). 6 indexed citations
20.
McGarry, Andrew, Karl Kieburtz, Victor Abler, et al.. (2017). Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington’s Disease. Journal of Huntington s Disease. 6(3). 189–199. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. De Domenico Breakdown of academic impact, for papers by Martha E. Trieschmann Breakdown of academic impact, for papers by Sanjeet Pakrasi Breakdown of academic impact, for papers by Tilak Mendis Breakdown of academic impact, for papers by Nataša Klepac Breakdown of academic impact, for papers by Ariane Park Breakdown of academic impact, for papers by C. Debieuvre Breakdown of academic impact, for papers by Kathrin Marini Breakdown of academic impact, for papers by Margherita Torti Breakdown of academic impact, for papers by Daun Bahr
Rankless by CCL
2026